February 2011 Br J Cardiol 2011;18:34-6
Richard J Jabbour, Dion Stub, Antony S Walton
Abstract
Introduction
Balloon aortic valvuloplasty (BAV) was first developed by Alain Cribier over 30 years ago for the management of aortic stenosis (AS).1 It was initially met with great enthusiasm due to its minimally invasive nature and possible alternative to surgery, but later fell from grace due mainly to high restenosis and complication rates. In addition, suboptimal results were obtained when compared with surgical aortic valve replacement (SAVR).2 However, the evolution of techniques and devices culminating in transcatheter aortic valve implantation (TAVI) has drastically shifted the treatment options for high-risk patients with severe AS.
T
|
Full text